Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: Insmed Incorporated has announced the granting of inducement awards to 10 new employees, complying with NASDAQ Listing Rule 5635(c)(4). Each new hire received stock options, allowing them to purchase a total of 136,060 shares at a price of $20.75, reflecting the company's commitment to attracting talent. Insmed continues to pursue its mission to develop treatments for serious and rare diseases while maintaining a robust pipeline of investigational therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed has granted inducement awards to 10 new employees, indicating growth and expansion.
  • The company is making material inducements to attract talent, which shows confidence in future operations.
  • Insmed continues to develop treatments for serious and rare diseases, reflecting strong pipeline prospects.

Full Press Release Details

BRIDGEWATER, N.J. , July 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on July 3, 2023 to purchase an aggregate 136,060 shares of Insmed common stock at an exercise price of $20.75 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 bryan.dunn@insmed. com
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What company granted inducement awards to new employees?

Insmed Incorporated granted inducement awards to 10 new employees.

When were the employee stock options granted?

The stock options were granted on July 3, 2023.

What is the exercise price for the stock options?

The exercise price for the stock options is $20.75 per share.

How long is the term for the stock options?

The term for the stock options is 10 years.

What is Insmed's mission?

Insmed aims to transform the lives of patients with serious and rare diseases.

Last updated: Jul 7, 2023